Exelixis announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival. CONTACT-03 evaluated cabozantinib in combination with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear cell or non-clear cell renal cell carcinoma who progressed during or after immune checkpoint inhibitor therapy. The safety profile of the combination of cabozantinib and atezolizumab observed in the trial was consistent with the known safety profiles for each single agent, and no new safety signals were identified with the combination. Detailed findings will be presented at an upcoming medical meeting.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL:
- Bristol-Myers’ Opdivo and Exelixis’ Cabometyx show durable survival in carcinoma
- Exelixis, Sairopa announce FDA clearance for ADU-1805 IND application
- Exelixis sees FY23 revene $1.775B-$1.875B, consensus $1.84B
- Exelixis reports Q4 EPS (3c), consensus (12c)
- Exelixis options imply 3.8% move in share price post-earnings
Questions or Comments about the article? Write to editor@tipranks.com